InChI:InChI=1/C54H69N11O10S2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74)
The present application discloses peptid...
A solid phase method for synthesizing a ...
The present invention relates to the use...
Pharmaceutical compositions containing g...
H-D-β-Nal-Cys-(Acm)-Tyr-D-Trp-Lys-Val-Cys(Acm)-Thr-NH2
lanreotide
| Conditions | Yield |
|---|---|
|
With
iodine; acetic acid;
In
methanol;
at 55 ℃;
for 0.25h;
Inert atmosphere;
|
350 mg |
Fmoc-Tyr(Clt)-OH
Fmoc-Val-OH
Boc-Lys(Boc)-OH
Fmoc-Thr-NH2
Boc-D-2Nal-OH
Fmoc-Trp-OH
N-(9-fluorenylmethoxycarbonyl)-S-trityl-L-cysteine
lanreotide
| Conditions | Yield |
|---|---|
|
Fmoc-Thr-NH2;
With
benzotriazol-1-ol; diisopropyl-carbodiimide;
In
1-methyl-pyrrolidin-2-one; dichloromethane;
at 0 - 30 ℃;
With
piperidine;
In
1-methyl-pyrrolidin-2-one;
Fmoc-Tyr(Clt)-OH; Fmoc-Val-OH; Boc-Lys(Boc)-OH; Boc-D-2Nal-OH; Fmoc-Trp-OH; N-(9-fluorenylmethoxycarbonyl)-S-trityl-L-cysteine;
Further stages;
|
H-D-β-Nal-Cys-(Acm)-Tyr-D-Trp-Lys-Val-Cys(Acm)-Thr-NH2
Fmoc-Tyr(Clt)-OH
Fmoc-Val-OH
Boc-Lys(Boc)-OH
Address：RMD5 5/F KING YIP FACTORY BLDG NO. 59 KING YIP ST KWUN TONG HONG KONGEmail：nancy@huajbio.com
Tel：8615230827325Phone： 8615230827325/8615324101521
